Tools & Techniques

Sessions spanning chemoproteomics, AI-driven proteomics, biotherapeutic characterization, single-cell omics, and spatial multiomics all pointed toward mass spectrometry’s growing role in drug discovery and development.

Explore key considerations for improving molecular biology workflows through centralized design, data management, and collaborative research practices.

The fully-automated system can complete a full drug discovery cycle in a matter of hours rather than weeks.

New instrument launches from two major vendors at this year's conference reflected shared priorities: higher proteome coverage, richer characterization of complex biotherapeutics, and tighter integration of AI. 

Advanced mass spectrometry and multidimensional separation strategies are improving the characterization of proteins, peptides, and complex biotherapeutics.

Explore how confocal live-cell imaging can reveal immune-tumor interactions and cytotoxic responses in three-dimensional tumor spheroid models.

The novel platform, called single-cell spatial pharmacobiology, revealed new insights into drug delivery of an antibody in Phase 1 trials.

From fleet-level monitoring to faster quantitative workflows, new expectations are emerging for how mass spectrometry platforms support decision-making at scale.

The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.

The toughest problem to solve in drug development may not be finding new medicines, but building the infrastructure to make them reliably.

Discover how patient-derived organoids can be applied throughout the oncology drug development pipeline, demonstrated in colorectal cancer research.

Discover how patient-derived organoids can be applied throughout the oncology drug development pipeline, demonstrated in colorectal cancer research.